COCP
Cocrystal Pharma, Inc.
$0.9900
-1.98%
$13.7M
No data for this timeframe.
Vol
Market Cap$13.7M
Cap SizeNano Cap
Inst. Holders12 funds
Inst. Value$528.5K
Inst. Activity0 buys / 2 sells
Insider Activity2B / 0S
Insider Net $$67.2K
Reddit Sentiment39° Cool
SEC Reports8
Recent Activity
Jun 9, 2026
SEC
Cocrystal Pharma appointed James Sapirstein as CEO, replacing co-CEOs Sam Lee and James Martin, who remain as President/
8-K — Impact 2/10
Jun 3, 2026
SEC
Cocrystal Pharma appointed James Sapirstein as CEO, effective immediately, replacing co-CEOs Sam Lee and Jim Martin. Lee
8-K — Impact 4/10
Jun 3, 2026
Insider
SAPIRSTEIN JAMES was granted 235,000 shares
Chief Executive Officer
May 27, 2026
SEC
Cocrystal Pharma filed a DEFA14A notice providing the logistics for its 2026 Annual Meeting of Stockholders to be held v
DEFA14A — Impact 2/10
May 18, 2026
earnings_calendar
COCP Q1 2026 Earnings Scheduled — 2026-05-18
Feb 24, 2026
Insider
FROST PHILLIP MD ET AL bought 20,000 shares
Director @ $0.9976 ($20.0K)
Feb 6, 2026
Insider
FROST PHILLIP MD ET AL bought 50,000 shares
Director @ $0.9456 ($47.3K)
Inst.
MORGAN STANLEY — NEAR_EXIT
948 shares ($928.00)
Price Targets
Historical data — last covering-analyst action Jun 2025. No current recommendation available.
$8.00 (Jun 2025)
Current $0.9949
Low $6.00
Median $8.00
High $10.00
3 analysts
$6.00
$10.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 20, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 22, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 14, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 4, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 20, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.17 | $-0.18 — $-0.15 | 18% YoY | 2 |
| Next Q | $-0.17 | $-0.19 — $-0.16 | 8% YoY | 2 |
| Current FY | $-0.69 ▼ -2.2% | $-0.76 — $-0.61 | 12% YoY | 2 |
| Next FY | $-0.64 | $-0.64 — $-0.64 | 7% YoY | 1 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $242.4K | — |
| RENAISSANCE TECHNOLOGIES LLC | $125.2K | — |
| BlackRock, Inc. | $74.5K | — |
| Neuberger Berman Group LLC | $32.2K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | SAPIRSTEIN JAMES | A | $0.00 |
| Feb 24, 2026 | FROST PHILLIP | BUY | $20.0K |
| Feb 6, 2026 | FROST PHILLIP | BUY | $47.3K |
Reddit Sentiment
39°
Cool
Bearish
Neutral
Bullish
12 institutional holders with $528.5K total value (523,280 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, RENAISSANCE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 51 | $0.00 | 0.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 239,971 | $242.4K | 45.9% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 123,928 | $125.2K | 23.7% | — |
| 4 | BlackRock, Inc. | 73,746 | $74.5K | 14.1% | — |
| 5 | Neuberger Berman Group LLC | 31,886 | $32.2K | 6.1% | — |
| 6 | VANGUARD FIDUCIARY TRUST CO | 24,016 | $24.3K | 4.6% | — |
| 7 | STATE STREET CORP | 20,543 | $20.7K | 3.9% | — |
| 8 | WELLS FARGO & COMPANY/MN | 7,039 | $7.1K | 1.3% | TRIM -56.5% |
| 9 | MORGAN STANLEY | 948 | $957.00 | 0.2% | NEAR_EXIT -83.8% |
| 10 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 817 | $825.00 | 0.2% | — |
| 11 | FMR LLC | 334 | $337.00 | 0.1% | — |
| 12 | CITIGROUP INC | 1 | $1.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | NEAR_EXIT | 5,863 | 948 | -83.8% | $928.00 | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 1,812 | 788 | -56.5% | $772.00 | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 21,915 | 571 | -97.4% | $714.00 | 2025-Q3 |
| UBS Group AG | ADD | 16,806 | 21,915 | +30.4% | $32.7K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 6 | 1,812 | +30100.0% | $2.7K | 2025-Q2 |
| UBS Group AG | DOUBLED | 6,130 | 16,806 | +174.2% | $23.9K | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 64,346 | 5,863 | -90.9% | $8.3K | 2025-Q1 |
| UBS Group AG | DOUBLED | 910 | 6,130 | +573.6% | $12.4K | 2024-Q4 |
2 unique insiders with 3 transactions. Net insider value: $67.2K ($67.2K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | SAPIRSTEIN JAMES | Chief Executive Officer | AWARD | 235,000 | — | — |
| Feb 24, 2026 | FROST PHILLIP MD ET AL | Director | BUY | 20,000 | $0.9976 | $20.0K |
| Feb 6, 2026 | FROST PHILLIP MD ET AL | Director | BUY | 50,000 | $0.9456 | $47.3K |
8 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 1 mixed, 4 neutral. Avg impact: 4.9/10.
NEUTRAL
8-K
2/10
Cocrystal Pharma appointed James Sapirstein as CEO, replacing co-CEOs Sam Lee and James Martin, who
Jun 9, 2026
NEUTRAL
8-K
4/10
Cocrystal Pharma appointed James Sapirstein as CEO, effective immediately, replacing co-CEOs Sam Lee
Jun 3, 2026
NEUTRAL
DEFA14A
2/10
Cocrystal Pharma filed a DEFA14A notice providing the logistics for its 2026 Annual Meeting of Stock
May 27, 2026
BULLISH
8-K
6/10
Cocrystal Pharma announced the discovery of novel pan-viral inhibitors targeting hantavirus, bunyavi
May 26, 2026
NEUTRAL
PRESS-RELEASE
5/10
Cocrystal Pharma reported Q1 2026 EPS of -$0.17, missing consensus of -$0.15 by 13.3%, and recognize
May 15, 2026
BEARISH
EFFECT
7/10
Cocrystal Pharma's $150M shelf registration (S-3) became effective on May 1, 2026, allowing the comp
May 4, 2026
MIXED
8-K
6/10
Cocrystal Pharma reported a net loss of $8.8 million ($0.78/share) for 2025, a significant improveme
Apr 21, 2026
BULLISH
8-K
7/10
Cocrystal Pharma received FDA Fast Track designation for CDI-988, its oral antiviral candidate for n
Apr 2, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jun 2025): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jun 2025. No current recommendation available.
$8.00 mean target (Jun 2025)
$6.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $0.9949 |
| Target Low | $6.00 |
| Target Mean | $8.00 |
| Target Median | $8.00 |
| Target High | $10.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.17 | $-0.18 | $-0.15 | 17.5% | +0.0% | — | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.17 | $-0.19 | $-0.16 | 7.9% | +0.0% | — | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-0.69 | $-0.76 | $-0.61 | 12.2% | -2.2% | — | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-0.64 | $-0.64 | $-0.64 | 6.6% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.165 | |
| 7d ago | $-0.165 | |
| 30d ago | $-0.165 | |
| 60d ago | $-0.195 | +0.030 |
| 90d ago | $-0.195 | +0.030 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 20, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 22, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 4, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 20, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 3, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 4, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 4, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 15, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 11, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 2, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 24, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 24, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Nov 7, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
39°
Cool
Bearish
Neutral
Bullish
5 mentions
0 bullish
2 bearish
5 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 8, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 8, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 2, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 2, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
COCP Cocrystal Pharma Inc
▲ 1
💬 1
⚡ 0.5
$COCP FDA Fast Track
▲ 1
💬 0
⚡ 0.5
$COCP FDA FASTTRACK
▲ 1
💬 1
⚡ 0.5
May 18, 2026
earnings_calendar
COCP Q1 2026 Earnings Scheduled — 2026-05-18
May 15, 2026
earnings
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
<p align="justify"><b>BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- </b><a href="https://www.globenewswire.com/Tracker?data=bXuAIp6ttts2B0awCUHaQ
May 13, 2026
earnings_calendar
COCP Q1 2026 Earnings Scheduled — 2026-05-13
Apr 30, 2026
other
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
<p align="justify"><b>BOTHELL, Wash., April 30, 2026 (GLOBE NEWSWIRE) -- </b><a href="https://www.globenewswire.com/Tracker?data=TFmqYSBnXcRmMSn4-Yg
Apr 8, 2026
short_interest
FTD: COCP — 395,523 shares ($0.6M) failed to deliver
Settlement: 20260408, Price: $1.47, FTD Value: $581,418.81, COCRYSTAL PHARMA INC COM PAR $
Apr 7, 2026
short_interest
FTD: COCP — 643,504 shares ($1.0M) failed to deliver
Settlement: 20260407, Price: $1.50, FTD Value: $965,256, COCRYSTAL PHARMA INC COM PAR $
Apr 6, 2026
earnings_calendar
COCP Q4 2025 Earnings After Market Close — 2026-04-06
Apr 6, 2026
short_interest
FTD: COCP — 1,265,298 shares ($1.9M) failed to deliver
Settlement: 20260406, Price: $1.51, FTD Value: $1,910,599.98, COCRYSTAL PHARMA INC COM PAR $
Apr 2, 2026
short_volume
Short Volume: COCP — 57.4% short (27.8M / 48.5M)
Short: 27,833,634 | Exempt: 234,756 | TRF Vol: 48,521,580 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)